The objective of this contract is to develop camelid vhhs that are capable of significantly (at least 5-fold improvement)enhancing GP120 expression in mammalian cells and applicable for rapid and…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93019C00009
- Awardee
-
Abzyme Therapeutics LLC UEI H2MLEFWV36N6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,815
Award facts
- Opportunity
-
- SBIRPHS20191 Solicitation number
- Nanoparticle Delivery of HIV Env Trimer for Inducing Somatic Hypermutation and bNAb Award Notice · Posted Jun 29, 2018
- Contract value 100% obligated
- $299,815.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Pottstown, PA 19464, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $299,815 |
About this award
This is a Firm Fixed Price contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Abzyme Therapeutics LLC, a minority-owned small business, under the Small Business Innovation Research (SBIR) program. The objective of the $299,815.00 Phase I contract is to develop camelid variable heavy chain antibody fragments (VHH) that can significantly enhance the expression of the HIV envelope glycoprotein gp120 in mammalian cells, enabling rapid and scalable gp120 protein purification. This research supports the agency's efforts to improve production of this key HIV vaccine antigen. Abzyme Therapeutics is a biopharmaceutical company that has received multiple NIH grants to develop modular antibody fragments for immunotherapy applications, including inhibiting complement activation and stimulating nerve growth for multiple sclerosis, and targeting retinal neovascular diseases and pemphigus.
Description
The objective of this contract is to develop camelid vhhs that are capable of significantly (at least 5-fold improvement)enhancing GP120 expression in mammalian cells and applicable for rapid and scalable GP120 protein purification.
Quick answers
Who was awarded contract 75N93019C00009?
75N93019C00009 was awarded to Abzyme Therapeutics LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 31, 2019.
How much is contract 75N93019C00009 worth?
The government has obligated $299,815 on 75N93019C00009.
Was contract 75N93019C00009 competed?
The extent of competition for 75N93019C00009 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award